LB Pharmaceuticals Inc
LBRX
Company Profile
Business description
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
Contact
One Pennsylvania Plaza
Suite 1025
New YorkNY10119
USAT: +1 212 605-0300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
stocks
Most popular shares in SMSFs
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,183.30 | 36.30 | -0.39% |
| CAC 40 | 7,934.26 | 16.26 | 0.21% |
| DAX 40 | 24,387.93 | 146.47 | 0.60% |
| Dow JONES (US) | 46,089.14 | 609.54 | 1.34% |
| FTSE 100 | 9,442.87 | 15.40 | 0.16% |
| HKSE | 25,889.48 | 400.84 | -1.52% |
| NASDAQ | 22,691.76 | 487.33 | 2.19% |
| Nikkei 225 | 48,088.80 | 491.64 | -1.01% |
| NZX 50 Index | 13,351.92 | 115.34 | -0.86% |
| S&P 500 | 6,658.31 | 105.80 | 1.61% |
| S&P/ASX 200 | 8,882.80 | 36.30 | -0.41% |
| SSE Composite Index | 3,889.50 | 7.53 | -0.19% |